AESARA

Exciting New Partnership at WVU School of Pharmacy! We are excited to announce the launch of a new pre-doctoral fellowship at the West Virginia University School of Pharmacy, in collaboration with AESARA, a leader in Health Economics and Outcomes Research (HEOR) and Market Access (MA) consulting. This fellowship, housed in the Department of Pharmaceutical Systems and Policy (PSP), will provide graduate students with invaluable hands-on experience in outcomes research, reimbursement, and access strategies. Through this partnership, we are bridging the gap between academia and industry, giving fellows the opportunity to gain expertise in HEOR and work alongside top experts in the pharmaceutical industry. We look forward to seeing the amazing contributions of future fellows and the continued impact of this collaboration! https://lnkd.in/eJ-t7DM4

Recent changes in HEOR functions among leading pharmaceutical companies reveal limited internal recognition of HEOR’s importance, even as external demand for evidence of value remains high. AESARA benchmarked HEOR functions in Biopharma companies to identify strengths and weaknesses of HEOR organization architecture, and areas for improvement in value & evidence generation. ?? KEY TREND: HEOR groups struggle to effectively disseminate HEOR deliverables and therefore risk the perception of being overly academic-/publication-focused. There is an unmet need to effectively package and communicate HEOR evidence to end customers to increase the business impact of HEOR deliverables. ?? Read our recently published article to learn more on how dissemination is critical to HEOR proving its own worth. ?? https://lnkd.in/gxwuivGe To learn more about our HEOR benchmarking report visit: https://lnkd.in/eEmBPGu9 #HEOR #Biopharma #PharmaInsights #Benchmarking #ValueEvidence

Data analytics is rapidly transforming Medical Affairs by providing the insights needed to make more informed, evidence-based decisions. From strategic planning (e.g., KOL mapping, research prioritization) to stakeholder engagement (e.g., engagement patterns, digital behavior analysis) and impact measurement (e.g., scientific exchange outcomes, practice pattern changes), analytics is driving higher value across the board. By leveraging real-world data to guide evidence generation (e.g., site selection, feasibility assessments) and by forecasting future trends to ensure future planning (e.g., capability gap analysis, identifying innovation opportunities), Medical Affairs teams can stay ahead of the curve. When utilized effectively, data analytics enables robust decision-making, streamlined collaboration, and impactful stakeholder engagement—ultimately elevating patient outcomes and driving organizational success. How is your team using data analytics to inform Medical Affairs strategy? Let’s connect at MAPS 2024 #MedicalAffairs #DataAnalytics #HealthcareInnovation #EvidenceBasedDecisionMaking #Pharma #MAPS

Meet our JCA expert! We’re looking forward to an action-packed week at the World EPA Congress! Our team will be there to delve into the newest market access and regulatory developments, as well as discussing the latest JCA updates. We’re also delighted to have Catherine Chamoux ?join us to discuss emerging insights. If you’re attending, be sure to stop by and connect with us—we’d love to hear your perspectives on how these developments are shaping our industry and where we’re heading next. Connect with Catherine in Amsterdam! #EPACongress #Pharma #HealthcareInnovation #JCA #MarketAccess #PatientAccess

?? World EPA Congress Session Alert ?? Join us on Tuesday, March 4, to learn more about how biopharma organizations can achieve pre-launch success by building a "best practice organization" in global market access and elevating market access to enable successful launches Connect with Amy W. in Amsterdam! #EPACongress #Pharma #HealthcareInnovation #MarketAccess #PatientAccess

?? World EPA Congress Session Alert ?? Join us for a timely discussion on the evolving regulatory landscape in Europe—including the new HTA and JCA processes—and the pressing challenges Governmental Agencies and Health Plans face. Our expert speakers will share insights into successful collaborations with the pharmaceutical industry and highlight future opportunities centered on real-world evidence, innovative contracting, and international partnerships. We’ll also explore practical strategies to overcome barriers, such as regulatory hurdles and data sharing, to foster trust and advance patient access to care. Connect with Martin Rost in Amsterdam! #EPACongress #Pharma #HealthcareInnovation #MarketAccess #PatientAccess

?? POLL ?? The evolution of medical affairs requires new approaches to measuring and communicating value. What is your greatest challenge? Share your perspective in the comments and let your medical affairs colleagues know how you are tackling the issue. #MedicalAffairs #MAPSNOLA2025 #MAPSEvent #JoinTheMovement #AESARA #MedicalExcellence #BioPharma

In the past, Medical affairs teams have struggled with demonstrating their full strategic value.? Traditional quantitative measures – studies completed, publications generated, advisory boards conducted and counting MSL engagements – tell part of the story.? ? The real value of medical affairs can be demonstrated through solid outcomes:? ? ?? Scientific evidence shapes impactful value propositions? ? ?? Scientific communication enables access and shapes clinical practice? ? ?? Stakeholder insights influence strategy? ? ?? Cross-functional collaboration drives business impact? ? ?? What is the key?? Building frameworks that incorporate both quantitative and qualitative measures to tell the story.? Looking beyond ‘how many’ and capturing ‘what changed.’? ? Join us at MAPS 2025 to explore innovative approaches to measuring and communicating medical affairs' strategic value. ?Contact us here: https://lnkd.in/gZZZCXtg? #MedicalAffairs #MAPSNOLA2025 #MAPSEvent #JoinTheMovement #AESARA #MedicalExcellence #BioPharma?

Connect with us at the World EPA Congress on March 5-6! Our team is excited to attend and looks forward to discussing the latest insights in Market Access, RWE, Rare Diseases, Pre-launch Success, Pricing, and more. Joining us at the conference are Ruslan Horblyuk, Martin Rost, and Amy W., and we can’t wait to share our perspectives—and hear yours. See you in Amsterdam! #EPACongress #Pharma #HealthcareInnovation #MarketAccess #PatientAccess #Pricing #Consulting #Innovation

Medical Affairs continues to evolve as a strategic cornerstone in biopharma, driven by three key shifts in recent years: 1?? Strategic Leadership: Driving product success across the lifecycle through insight-driven evidence generation and dissemination planning. 2?? Value Communication:?Transforming scientific engagement through tailored approaches that drive measurable changes in product access and prescribing behaviors. 3?? Impact Measurement:?Building comprehensive frameworks that capture and elevate medical affairs strategic value across the organization. Ready to elevate your medical affairs function??Connect with John Byrd and Chad Patel to discuss how AESARA can help transform your medical affairs team and drive value. Contact us here: https://lnkd.in/gZZZCXtg #MedicalAffairs #MAPSNOLA2025 #MAPSEvent #JoinTheMovement?#AESARA #MedicalExcellence #BioPharma